Next Article in Journal
Concurrent Use of Anticholinergic and Antidementia Medicines in Older Adults with Dementia: A Systematic Review of Prevalence, Predictors and Clinical Outcomes
Previous Article in Journal
Metronidazole Susceptibility Patterns in European Bacteroides, Phocaeicola, and Parabacteroides Clinical Isolates—A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medical Sciences
Volume 14
Issue 4
10.3390/medsci14040425
medsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients

by
Aimilios Kaklamanos
1,
Vasileios Serepisios
1,
Sofia Chelioti
1,
Kalliopi Zervakou
1,
George Christodoulou
1,
Abraham Pouliakis
2,
Konstantina Mikelopoulou
1,
Daphnie Germanou
1,
Ilias Tsinokou
1,
Dimitrios Dorotheos Papadakis
1,
Christos Tsironis
1 and
Theodoros Androutsakos
1,*
1
Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
2
2nd Department of Pathology, University Hospital “Attikon”, National and Kapodistrian University of Athens, 12461 Athens, Greece
*
Author to whom correspondence should be addressed.
Med. Sci. 2026, 14(4), 425; https://doi.org/10.3390/medsci14040425
Submission received: 11 June 2026 / Revised: 12 July 2026 / Accepted: 21 July 2026 / Published: 24 July 2026
(This article belongs to the Section Critical Care Medicine)
Browse Figure
Versions Notes

Abstract

Background/Objectives: Acutely ill patients in hospital are at high risk for thrombosis, even post-discharge. However, the safest and most effective strategy for thromboprophylaxis in such patients is still under debate. Our aim was to compare the subcutaneous use of low-dose prophylactic enoxaparin versus intermediate-dose tinzaparin. Methods: Patients in an internal medicine clinic of a tertiary hospital in Athens, Greece, with increased risk for thrombosis (PADUA score ≥ 4) received either intermediate-dose tinzaparin (8000 anti-Xa units) or 40 mg enoxaparin as thromboprophylaxis. Efficacy and adverse effects were evaluated and compared up to 14 days post-discharge. Results: A total of 251 patients who received tinzaparin were compared with 95 patients under enoxaparin thromboprophylaxis. No statistically significant difference was found in the number of bleeding and/or clinically evident thrombotic events between the two groups [6 versus 14 bleeding (p = 0.2603) events and 0 versus 1 venous thrombotic event (p = 0.999) in the enoxaparin and tinzaparin groups, respectively]. Moreover, no difference was found in length of stay [enoxaparin: 10 days (95%CI: 9–12 days); tinzaparin: 8 days (95%CI: 8–10 days, HR = 1.18, 95%CI: 0.91–1.54, p = 0.2] or mortality [11 deaths with enoxaparin (11.58%, 95%CI: 6.59–19.55%) and 50 deaths with tinzaparin (19.92%, 95%CI: 15.45–25.30%, OR: 1.9, 95%CI: 0.94–3.83, p = 0.069)]. The use of thromboprophylaxis for two weeks post-discharge did not result in any bleeding or clinically evident thrombotic events in either group. Conclusions: In our cohort, the use of intermediate-dose tinzaparin was similar to the use of low-dose enoxaparin for patients with a high PADUA score in terms of thrombotic and/or bleeding events.
Keywords: tinzaparin; enoxaparin; thrombosis prophylaxis; bleeding tinzaparin; enoxaparin; thrombosis prophylaxis; bleeding

Share and Cite

MDPI and ACS Style

Kaklamanos, A.; Serepisios, V.; Chelioti, S.; Zervakou, K.; Christodoulou, G.; Pouliakis, A.; Mikelopoulou, K.; Germanou, D.; Tsinokou, I.; Papadakis, D.D.; et al. Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients. Med. Sci. 2026, 14, 425. https://doi.org/10.3390/medsci14040425

AMA Style

Kaklamanos A, Serepisios V, Chelioti S, Zervakou K, Christodoulou G, Pouliakis A, Mikelopoulou K, Germanou D, Tsinokou I, Papadakis DD, et al. Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients. Medical Sciences. 2026; 14(4):425. https://doi.org/10.3390/medsci14040425

Chicago/Turabian Style

Kaklamanos, Aimilios, Vasileios Serepisios, Sofia Chelioti, Kalliopi Zervakou, George Christodoulou, Abraham Pouliakis, Konstantina Mikelopoulou, Daphnie Germanou, Ilias Tsinokou, Dimitrios Dorotheos Papadakis, and et al. 2026. "Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients" Medical Sciences 14, no. 4: 425. https://doi.org/10.3390/medsci14040425

APA Style

Kaklamanos, A., Serepisios, V., Chelioti, S., Zervakou, K., Christodoulou, G., Pouliakis, A., Mikelopoulou, K., Germanou, D., Tsinokou, I., Papadakis, D. D., Tsironis, C., & Androutsakos, T. (2026). Intermediate-Dose Tinzaparin Versus Low-Dose Enoxaparin as Thromboprophylaxis in Hospitalized Internal Medicine Patients. Medical Sciences, 14(4), 425. https://doi.org/10.3390/medsci14040425

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop